Free tool
FAERS Monitor: Triptodur Kit
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208956 or its brand name (Triptodur Kit, Triptorelin Pamoate). Reports on generic versions are filed under their own applications.
Reports
3,354
Serious
2,156
64% of reports
Hospitalization
831
Death reported
198
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use289
- needle issue199
- disease progression133
- product dose omission issue125
- drug ineffective118
- headache114
- injection site pain104
- weight increased104
- ovarian hyperstimulation syndrome101
- vaginal haemorrhage95
- syringe issue90
- asthenia88
- fatigue85
- pyrexia82
- vomiting81
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 10 |
| 2006 | 3 |
| 2007 | 13 |
| 2008 | 14 |
| 2009 | 10 |
| 2010 | 24 |
| 2011 | 19 |
| 2012 | 19 |
| 2013 | 10 |
| 2014 | 29 |
| 2015 | 33 |
| 2016 | 19 |
| 2017 | 51 |
| 2018 | 180 |
| 2019 | 459 |
| 2020 | 378 |
| 2021 | 420 |
| 2022 | 309 |
| 2023 | 342 |
| 2024 | 331 |
| 2025 | 439 |
| 2026 | 238 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,805 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ovarian hyperstimulation syndromeSignal | 101 | 284.0 | 233.3 | 26,983 |
| needle issueSignal | 199 | 43.2 | 37.7 | 8,108 |
| syringe issueSignal | 90 | 32.4 | 26.4 | 2,697 |
| vaginal haemorrhageSignal | 95 | 13.8 | 11.3 | 1,111 |
| disease progressionSignal | 133 | 7.1 | 6.0 | 688 |
| weight increasedSignal | 104 | 2.9 | 2.4 | 130 |
| product dose omission issueSignal | 125 | 2.7 | 2.2 | 130 |
| injection site painSignal | 104 | 2.1 | 1.8 | 62 |
| off label useSignal | 289 | 2.1 | 1.9 | 166 |
| pyrexia | 82 | 1.5 | 1.2 | 13 |
| asthenia | 88 | 1.5 | 1.2 | 13 |
| headache | 114 | 1.1 | 1.0 | 2 |
| vomiting | 81 | 1.1 | 0.9 | 0 |
| fatigue | 85 | 0.7 | 0.6 | 12 |
| drug ineffective | 118 | 0.6 | 0.5 | 43 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.